| Q38782612 | A FGFR1 inhibitor patent review: progress since 2010. |
| Q37976467 | A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets |
| Q35116704 | A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors |
| Q36653663 | A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis |
| Q36161541 | Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer |
| Q34655335 | Angiogenesis and antiangiogenic agents in cervical cancer. |
| Q48431178 | Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat. |
| Q26826817 | Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives |
| Q37632167 | Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies |
| Q38085684 | Axitinib for the treatment of advanced non-small-cell lung cancer |
| Q38151193 | Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer |
| Q37851518 | Brivanib alaninate for cancer |
| Q35141906 | Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. |
| Q38048883 | Brivanib: a review of development |
| Q37039782 | By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy |
| Q38743040 | Clinical trials of antiangiogenic therapy for hepatocellular carcinoma |
| Q34436101 | Development and strategies of VEGFR-2/KDR inhibitors |
| Q39062384 | Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity |
| Q37428176 | Drug development in advanced colorectal cancer: challenges and opportunities |
| Q36989925 | Emerging drugs for the treatment of metastatic renal cancer. |
| Q34082909 | Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors |
| Q52668906 | Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations. |
| Q36923642 | Fibroblast growth factors, old kids on the new block |
| Q93185552 | Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer |
| Q51375392 | Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors. |
| Q34257497 | Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. |
| Q37631288 | Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition |
| Q92344153 | New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma |
| Q26738548 | New advances in targeted gastric cancer treatment |
| Q27693185 | Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors |
| Q39431960 | Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways |
| Q35108333 | Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy |
| Q35131258 | Rationale for targeting fibroblast growth factor receptor signaling in breast cancer |
| Q38188582 | Review of angiogenesis in hepatocellular carcinoma |
| Q38354294 | Role of the fibroblast growth factor receptor axis in cholangiocarcinoma |
| Q50107409 | SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models |
| Q35759606 | Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications |
| Q38690050 | Targeting FGFR in Squamous Cell Carcinoma of the Lung |
| Q37849781 | Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. |
| Q50951764 | The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. |
| Q37389768 | The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer |
| Q37686529 | Tyrosine kinase inhibitors to treat liver cancer |
| Q26797535 | Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma |
| Q36677407 | VEGF/VEGFR signalling as a target for inhibiting angiogenesis |